When Outpatient Drug Treatment Fails: Non-Complier or Non-Responder?: Identifying Non-Compliers as a Cost-Containment Tool

References

• Cramer J A, Mattson R H, Prevey M L, Scheyer R D, Ouellette V L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–3277
   PubMed Web of Science ®Google Scholar
• Kruse W, Weber E. Dynamics of drug regimen compliance—its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5
   PubMed Web of Science ®Google Scholar
• Averbuch M, Weintraub M, Pollack D J. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199–204
   Google Scholar
• Feinstein A R. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377–8
   PubMed Web of Science ®Google Scholar
• Jaillon P. Le bouchon-mémoire, une novelle mesure de l'observance du traitement. Lettre du Pharmacologue 1990; 4: 131
   Google Scholar
• Bond W S, Hussar D A. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48: 1978–88
   PubMedGoogle Scholar
• Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 1991; 41: 27–35
   PubMed Web of Science ®Google Scholar
• Psaty B M, Koepsell T D, Wagner E H, LoGerfo J P, Inui T S. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653–7
   PubMed Web of Science ®Google Scholar
• Rangno R E, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J 1982; 104: 473–8
   PubMed Web of Science ®Google Scholar
• Johnson B F, Whelton A, McMahon F G. Betaxolol vs atenolol in hypertension: a comparison of efficacy, duration of response, and effects of withdrawal. Am J Hypertension 1990; 3(5), Part II, 121 A, Abstract 1429
   Google Scholar
• Lasagna L. Noncompliance data and clinical outcomes: impact on health care. Primary Cardiology Suppl 1992; 1: 36–9
   Google Scholar
• Drehobl M, Kelsen S, Sahn S, Schleupner C, Puopolo A. Efficacy, safety, and compliance of cefixime QD compared with cefuroxime axetil BID in the treatment of bronchitis. Poster presented at American Osteopathic Association annual meeting, New Orleans, November, 31991
   Google Scholar
• Pullar T, Feely M. Problems of compliance with drug treatment: new solutions. Pharm J 1990; 245: 213–5
   Google Scholar
• Kruse W. Patient compliance with drug treatment-new perspectives on an old problem. Clin Investig 1992; 70: 163–6
   PubMedGoogle Scholar
• Matsui D, Hermann C, Braudo M, Ito S, Olivieri N, Koren G. Clinical use of the Medication Event Monitoring System: A new window into pediatric compliance. Clin Pharmacol ther 1992; 52: 102–3
   PubMed Web of Science ®Google Scholar
• Kass M A, Gordon M, Meltzer D W. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy. Am J Ophthalmol 1986; 101: 524–530
   PubMed Web of Science ®Google Scholar
• Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in organ transplant recipients. Transplantation Proceedings 1989; 21(1)833–834
   PubMed Web of Science ®Google Scholar
• Didlake R H, Dreyfus K, Kerman R H, Van Buren C T, Kahan B D. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplantation Proceedings 1988; 20(Suppl 3)63–69
   PubMed Web of Science ®Google Scholar
• Snodgrass W, Smith S, Trueworthy R, Bats T, Klopovitch P, Kisker S. Pediatric clinical pharmacology of 6-mercaptopurine: lack of compliance as a factor in leukemia relapse. Proc Am Soc Clin Oncol 1984; 3: 204
   Google Scholar
• Meichenbaum D, Turk D C. Facilitating Treatment Adherence: A Practitioner's Guidebook. Plenum, New York 1987
   Google Scholar
• Cramer J A, Scheyer R D, Mattson R H. Compliance declines between clinic visits. Arch Int Med 1990; 150: 1509–10
   PubMed Web of Science ®Google Scholar
• Gerson A C, Pegelow C H, Armstrong F D, Faust J. The efficacy of an intervention to increase maternal adherence to prophylactic penicillin. Poster presented at the 1992 annual meeting of the National Sickle Cell Disease Program, Nashville, TN, March, 14–181992
   Google Scholar
• Kruse W. Krankenhaus Bethanien. University of Heidelberg, Personal observations
   Google Scholar
• Pullar T, Birtwell A J, Wiles P G, Hay A, Feely M P. Use of a pharmacologic indicator to compare compliance with tablets prescribed once, twice, or three times daily. Clin Pharmacol ther 1988; 44: 540–5
   PubMed Web of Science ®Google Scholar
• Krüse W, Eggert-Krüse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behaviour—a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991; 41: 589–92
   PubMed Web of Science ®Google Scholar
• Helping patients to make the best use of medicines. Drug therap Bull Jan 7, 1991; 39(1), Anon.
   Google Scholar
• Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol ther 1990; 48: 676–85
   PubMed Web of Science ®Google Scholar
• Kumar S, Haigh J RM, Rhodes L E, Peaker S, Davies J A, Roberts B E, Feely M P. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thrombosis Haemostasis 1989; 62: 729–32
   PubMed Web of Science ®Google Scholar
• Pullar T, Peaker S, Martin M FR, Bird H A, Feely M P. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Brit J Rheumatol 1988; 27: 381–4
   PubMedGoogle Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results: (I) Reduction in incidence of coronary heart disease; (II) the relationship of reduction in incidence or coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–374
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo M O, Frick H, et al. Lipid alternations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–51
   PubMed Web of Science ®Google Scholar
• Kruse W H-H. Compliance with treatment of hyperlipoproteinemia in medical practice and clinical trials. Compliance in Medical Practice and Clinical Trials, J A Cramer, B Spilker. Raven Press, New York 1991; 175–86
   Google Scholar
• Wood H F, Feinstein A R, Taranta A, Epstein J A, Simpson R. Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. III. Comparative effectiveness of three prophylaxis regimens in preventing streptococcal infections and rheumatic recurrences. Ann Int Med 1964; 60(suppl 5)31–46
   Google Scholar
• Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1992; 68(suppl 3)S49–S59
   PubMed Web of Science ®Google Scholar